Phosphoproteomic analysis of cell-based resistance to BRAF inhibitor therapy in melanoma

Frontiers in Oncology

Volumn 5, Issue MAY, 2015, Pages

  Parker, Robert ^a   Vella, Laura J ^b   Xavier, Dylan ^a   Amirkhani, Ardeshir ^a   Parker, Jimmy ^c   Cebon, Jonathan ^b   Molloy, Mark P ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c SOUTHPORT AND ORMSKIRK HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

BRAF; Drug resistance; Kinases; Label free quantitation; Mass spectrometry; Phosphoproteomics; Vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CASEIN KINASE II; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOPEPTIDE; PHOSPHOPROTEOME; PROTEIN KINASE C; PROTEOME; SOMATOMEDIN; UNCLASSIFIED DRUG; VEMURAFENIB;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELL LABELING; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL LINE; MELANOSOME; META ANALYSIS (TOPIC); PLASTICITY; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEOMICS;

EID: 84934298961     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00095     Document Type: Article

References (80)

1. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res (2003) 9:6483-8.
2. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 29:1239-46. doi:10.1200/JCO.2010.32.4327
3. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2012) 118:4014-23. doi:10.1002/cncr.26724
4. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 107:14903-8. doi:10.1073/pnas.1008990107
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 364:2507-16. doi:10.1056/NEJMoa1103782
6. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 363:809-19. doi:10.1056/NEJMoa1002011
7. Sullivan RJ, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene (2013) 32:2373-9. doi:10.1038/onc.2012.345
8. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer (2013) 49:1297-304. doi:10.1016/j.ejca.2012.11.019
9. Pritchard AL, Hayward NK. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res (2013) 19:2301-9. doi:10.1158/1078-0432.CCR-12-0383
10. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 12: 637-49. doi:10.1593/neo.10414
11. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem (2012) 287:28087-98. doi:10.1074/jbc.M112.377218
12. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 18:683-95. doi:10.1016/j.ccr.2010.11.023
13. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 508:118-22. doi:10.1038/nature13121
14. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 464:427-30. doi:10.1038/nature08902
15. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 464:431-5. doi:10.1038/nature08833
16. Mooz J, Oberoi-Khanuja TK, Harms GS, Wang W, Jaiswal BS, Seshagiri S, et al. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration. Sci Signal (2014) 7:ra73. doi:10.1126/scisignal.2005484
17. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 140:209-21. doi:10.1016/j.cell.2009.12.040
18. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 468:968-72. doi:10.1038/nature09627
19. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 106:20411-6. doi:10.1073/pnas.0905833106
20. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 480:387-90. doi:10.1038/nature10662
21. Kemper K, de Goeje PL, Peeper DS, van Amerongen R. Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Res (2014) 74:5937-41. doi:10.1158/0008-5472.CAN-14-1174
22. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 487:500-4. doi:10.1038/nature11183
23. Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov (2014) 4:816-27. doi:10.1158/2159-8290.CD-13-0424
24. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 19:290-302. doi:10.1111/j.1600-0749.2006.00322.x
25. Zipser MC, Eichhoff OM, Widmer DS, Schlegel NC, Schoenewolf NL, Stuart D, et al. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell Melanoma Res (2011) 24:326-33. doi:10.1111/j.1755-148X.2010.00823.x
26. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One (2011) 6:e28973. doi:10.1371/journal.pone.0028973
27. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther (2012) 11:909-20. doi:10.1158/1535-7163.MCT-11-0989
28. Roux PP, Thibault P. The coming of age of phosphoproteomics - from large data sets to inference of protein functions. Mol Cell Proteomics (2013) 12:3453-64. doi:10.1074/mcp.R113.032862
29. Wilkes EH, Casado P, Cutillas PR. Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies. Biochem Soc Trans (2014) 42:791-7. doi:10.1042/BST20140029
30. Alcolea MP, Casado P, Rodriguez-Prados JC, Vanhaesebroeck B, Cutillas PR. Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics (2012) 11:453-66. doi:10.1074/mcp.M112.017483
31. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell (2009) 34:115-31. doi:10.1016/j.molcel.2009.03.007
32. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2013) 3:158-67. doi:10.1158/2159-8290.CD-12-0386
33. Behren A, Anaka M, Lo PH, Vella LJ, Davis ID, Catimel J, et al. The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res (2013) 26:597-600.
34. Boersema PJ, Aye TT, van Veen TA, Heck AJ, Mohammed S. Triplex protein quantification based on stable isotope labeling by peptide dimethylation applied to cell and tissue lysates. Proteomics (2008) 8:4624-32. doi:10.1002/pmic.200800297
35. Parker R, Melathopoulos AP, White R, Pernal SF, Guarna MM, Foster LJ. Ecological adaptation of diverse honey bee (Apis mellifera) populations. PLoS One (2010) 5:e11096. doi:10.1371/journal.pone.0011096
36. Ishihama Y, Rappsilber J, Mann M. Modular stop and go extraction tips with stacked disks for parallel and multidimensional peptide fractionation in proteomics. J Proteome Res (2006) 5:988-94. doi:10.1021/pr050385q
37. Wisniewski JR, Zougman A, Mann M. Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J Proteome Res (2009) 8:5674-8. doi:10.1021/pr900748n
38. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics (2014) 13:2513-26. doi:10.1074/mcp.M113.031591
39. Cox J, Mann M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinformatics (2012) 13(Suppl 16):S12. doi:10.1186/1471-2105-13-S16-S12
40. Vizcaino JA, Deutsch EW, Wang R, Csordas A, Reisinger F, Rios D, et al. Hermjakob, ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nature Biotechnology (2014) 32: 223-6.
41. Linding R, Jensen LJ, Pasculescu A, Olhovsky M, Colwill K, Bork P, et al. NetworKIN: a resource for exploring cellular phosphorylation networks. Nucleic Acids Res (2008) 36:D695-9. doi:10.1093/nar/gkm902
42. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res (2012) 40:D261-70. doi:10.1093/nar/gkr1122
43. Parker R, Clifton-Bligh R, Molloy MP. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition. Mol Cancer Ther (2014) 13:1894-906. doi:10.1158/1535-7163.MCT-13-0938
44. Bamburg JR, Bernstein BW. Roles of ADF/cofilin in actin polymerization and beyond. F1000 Biol Rep (2010) 2:62. doi:10.3410/B2-62
45. Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K, et al. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature (1998) 393:809-12. doi:10.1038/31735
46. Moriyama K, Iida K, Yahara I. Phosphorylation of Ser-3 of cofilin regulates its essential function on actin. Genes Cells (1996) 1:73-86. doi:10.1046/j.1365-2443.1996.05005.x
47. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol (2009) 10:778-90. doi:10.1038/nrm2786
48. Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases (2014) 5:e29846. doi:10.4161/sgtp.29846
49. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev (2002) 16:1587-609. doi:10.1101/gad.1003302
50. Barac A, Basile J, Vazquez-Prado J, Gao Y, Zheng Y, Gutkind JS. Direct interaction of p21-activated kinase 4 with PDZ-RhoGEF, a G protein-linked Rho guanine exchange factor. J Biol Chem (2004) 279:6182-9. doi:10.1074/jbc.M309579200
51. Chikumi H, Barac A, Behbahani B, Gao Y, Teramoto H, Zheng Y, et al. Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential. Oncogene (2004) 23:233-40. doi:10.1038/sj.onc.1207012
52. Hufnagel A, Elger CE, Boker DK, Linke DB, Kurthen M, Solymosi L. Activation of the epileptic focus during intracarotid amobarbital test. Electrocorticographic registration via subdural electrodes. Electroencephalogr Clin Neurophysiol (1990) 75:453-63. doi:10.1016/0013-4694(90)90132-4
53. Goold RG, Gordon-Weeks PR. Microtubule-associated protein 1B phosphorylation by glycogen synthase kinase 3beta is induced during PC12 cell differentiation. J Cell Sci (2001) 114:4273-84.
54. Pankova K, Rosel D, Novotny M, Brabek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci (2010) 67:63-71. doi:10.1007/s00018-009-0132-1
55. Vandamme N, Berx G. Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity. Front Oncol (2014) 4:352. doi:10.3389/fonc.2014.00352
56. Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol (2006) 16:1515-23. doi:10.1016/j.cub.2006.05.065
57. Smit MA, Maddalo G, Greig K, Raaijmakers LM, Possik PA, van Breukelen B, et al. ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma. Mol Syst Biol (2014) 10:772. doi:10.15252/msb.20145450
58. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 504:138-42. doi:10.1038/nature12688
59. Palmisano I, Bagnato P, Palmigiano A, Innamorati G, Rotondo G, Altimare D, et al. The ocular albinism type 1 protein, an intracellular G protein-coupled receptor, regulates melanosome transport in pigment cells. Hum Mol Genet (2008) 17:3487-501. doi:10.1093/hmg/ddn241
60. Innamorati G, Piccirillo R, Bagnato P, Palmisano I, Schiaffino MV. The melanosomal/lysosomal protein OA1 has properties of a G protein-coupled receptor. Pigment Cell Res (2006) 19:125-35. doi:10.1111/j.1600-0749.2006.00292.x
61. Giordano F, Bonetti C, Surace EM, Marigo V, Raposo G. The ocular albinism type 1 (OA1) G-protein-coupled receptor functions with MART-1 at early stages of melanogenesis to control melanosome identity and composition. Hum Mol Genet (2009) 18:4530-45. doi:10.1093/hmg/ddp415
62. Falletta P, Bagnato P, Bono M, Monticone M, Schiaffino MV, Bennett DC, et al. Melanosome-autonomous regulation of size and number: the OA1 receptor sustains PMEL expression. Pigment Cell Melanoma Res (2014) 27:565-79. doi:10.1111/pcmr.12239
63. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One (2008) 3:e2734. doi:10.1371/journal.pone.0002734
64. Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ, et al. Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Receptors Channels (1997) 5:193-9.
65. Piccirillo R, Palmisano I, Innamorati G, Bagnato P, Altimare D, Schiaffino MV. An unconventional dileucine-based motif and a novel cytosolic motif are required for the lysosomal and melanosomal targeting of OA1. J Cell Sci (2006) 119:2003-14. doi:10.1242/jcs.02930
66. Nakashima S. Protein kinase C alpha (PKC alpha): regulation and biological function. J Biochem (2002) 132:669-75. doi:10.1093/oxfordjournals.jbchem.a003272
67. Denning MF. Specifying protein kinase C functions in melanoma. Pigment Cell Melanoma Res (2012) 25:466-76. doi:10.1111/j.1755-148X.2012.01015.x
68. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol (1998) 18:790-8.
69. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, et al. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 11:447-60. doi:10.1016/j.ccr.2007.03.009
70. Vomastek T, Iwanicki MP, Burack WR, Tiwari D, Kumar D, Parsons JT, et al. Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction. Mol Cell Biol (2008) 28:6954-66. doi:10.1128/MCB.00925-08
71. Bagrodia S, Smeal T, Abraham RT. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. Pigment Cell Melanoma Res (2012) 25:819-31. doi:10.1111/pcmr.12007
72. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol (2006) 7:85-96. doi:10.1038/nrm1837
73. Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 73:4383-94. doi:10.1158/0008-5472.CAN-12-3385
74. Giles KM, Brown RA, Epis MR, Kalinowski FC, Leedman PJ. miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun (2013) 430:706-10. doi:10.1016/j.bbrc.2012.11.086
75. Shaw LM. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol (2001) 21:5082-93. doi:10.1128/MCB.21.15.5082-5093.2001
76. Meresse S, Hoflack B. Phosphorylation of the cation-independent mannose 6-phosphate receptor is closely associated with its exit from the trans-Golgi network. J Cell Biol (1993) 120:67-75. doi:10.1083/jcb.120.1.67
77. Osipo C, Dorman S, Frankfater A. Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors. Exp Cell Res (2001) 264:388-96. doi:10.1006/excr.2000.5121
78. Becherel OJ, Jakob B, Cherry AL, Gueven N, Fusser M, Kijas AW, et al. CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response. Nucleic Acids Res (2010) 38:1489-503. doi:10.1093/nar/gkp1149
79. Loizou JI, El-Khamisy SF, Zlatanou A, Moore DJ, Chan DW, Qin J, et al. The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell (2004) 117:17-28. doi:10.1016/S0092-8674(04)00206-5
80. Silvy F, Lissitzky JC, Bruneau N, Zucchini N, Landrier JF, Lombardo D, et al. Resistance to cisplatin-induced cell death conferred by the activity of organic anion transporting polypeptides (OATP) in human melanoma cells. Pigment Cell Melanoma Res (2013) 26:592-6. doi:10.1111/pcmr.12108